Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.


  1. Advanced Patent Search
Publication numberUS3044938 A
Publication typeGrant
Publication dateJul 17, 1962
Filing dateJul 1, 1955
Priority dateJul 1, 1955
Publication numberUS 3044938 A, US 3044938A, US-A-3044938, US3044938 A, US3044938A
InventorsHalley Stanley G
Original AssigneeSandoz Chemical Works Inc
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Sustained action pharmaceutical tablets
US 3044938 A
Abstract  available in
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

July 17, 1962 s. G. HALLEY SUSTAINED ACTION PHARMACEUTICAL TABLETS Filed July 1, 1955 INVENTOR STANLEY G. HALLEYY ATTORNEYS United States Patent Ofiice Chemical Works, Inc., New York, N.Y., a corporation of New York Filed July 1, 1955, Ser. No. 519,560 r Qlaim. (or. rep-s2 The present invention relates to sustained action pharmaceutical tablets and to the manufacture thereof.

There are many cases where it is desirable that medication administered to a patient be of brief and limited duration; this type of medication generally represents no problem.- There are other cases where it is desirable that orally administered medication take effect at a particular place in the body. This type of problem is present where, for example, it is desired that the drug take effect in the intestine and not in the stomach. The problem is readily solved by providing the drugusually a single drug-with an enteric coating. which does not dissolve in the acid medium of the stomach, but does dissolve in the alkaline medium of the intestine. There are still other cases where it is desirable that a prolonged or sustained effect he obtained from a single dose of orally administered drug. For example, where a particular dose of a drug would normally exert its action for 4 hoursso that sustained action through the night, for instance, requires awakening of the patient at 4-hour intervals for re-administration of the medicament-it may be desirable to extend or prolong the action for a period of perhaps 8 or more hoursso that a dose taken just before retiring for the night, for instance, will exert its intended effect throughout the night and will obviate the necessity of awakening the patient for the purpose of administering additional medicament. In some cases, a medicament, if allowed to exert its entire effect at once, may give rise to undesired side-effects such as drowsiness or the like. Prolonging the action of such a drug, in the sense of stretching out the effect (including the side-effect or effects) over a period of time which is considerably longer than normal, may dilute the undesired effects to such an extent as effectually to obviate the sensation of their presence; the result thus, in effect, is to obtain the desired beneficial effect without undesired side-effect.

The present invention is concerned with the embodiment ofmedicamentsprefera1bly in or-ally administerable form (compressed tablets)-of the prolonged or sustained action category. Medicaments of this type are known which involve periodic, timed, or repeated delayed disintegration products, wherein medication is contained in several layers, with the outer layer disintegrating first, followed by the disintegration of an inner layer (core) or layers, protective coatings or the like usually being provided between the several layers. In contradistinction to this type of prolonged action medicament, the products of the present invention are of the continuous disintegration type, i.e. they disintegrate gradually over a prolonged period of time, thus giving the desired sustained action.

The present invention is based upon the principle of incorporating into at least some portions of the medicamentwhich is itself constituted by an active ingredient Thus, where a per se known medicament is being con-' verted into sustained action form according to the present invention, the new tablet may comprise portions of such known medicament in unaltered form; if the normal color thereof is e.g. white, the portions of the new product constituted by such known medicament will continue to be white. Other portions of the new product which may contain one action-retardant according to the invention will be distinguished from the first-mentioned portions by being colored (e.g. with the aid of a pharmaceuticallytolerable coloring material). Still other portions which may contain another action-retardant will be distinguished from the already-mentioned portions by means of a different colorant.

Among other things, the multi-colored feature of the invention operates to identify the sustained action variant of the medicament from the normal variant thereof. It also tends to impress upon the patient the m ulti-com ponent characterat least from the standpoint of period of activityof the medicament.

As will hereinafter more clearly appear, the product of the invention is in effect an uncoated, non-enteric, multicolored tablet comprising portions of different extents of action (different action periods), the dilferential action being due to the integral incorporation, into said portions of retarded action, of materials-essentially resinous in character-which function simultaneously, in such portions, as action-retardant and binding agent.

Briefly stated, and taking a three-portion medicament by way of example, the products of the invention may be constituted as follows:

Medicament M is first made up in essentially conventional manner, for example by admixture with usual additaments, such as corn starch, milk sugar and the like, and is then granulated and sized, keeping only granules of desired or preferred size. A second batch of medicament M is then made up in essentially similar manner, except that there are included as further additarnents, a first action-retardant and binding agent AB and a coloring material D. This batch is also granulated and sized. A third batch of medicament M is then made up after the manner of the second batch, except that a different action retardant and binding agent AB and a different coloring material D are employed. This batch is also granulated and sized. The final tablets are then made up, on a conseveral differently colored Portions of which are of differential disintegrability in the body liquids, e.g. gastric juices. The result will be thatdue to the retardant action of the additamentsAB and AB--the corresponding 7 J portions will exert their action over a longer period of time than will the portions free from such action-retardants. Moreover, due to the differential retardant action of the agents AB and AB with respect to each other; I A

these will also be assimilated into the body at different rates, so that a sustained action results.

A number of concomitant action-retardant and binding agents may be employed for the purposes of the present invention. .Where more than 'one such agent is employed,

it isof course desirable that they be different in their disintegration retarding action. Presently preferred agents of this character are vinyl acetate (e.g. Bakelite Vinyl Resin AYAC) and refined shellac (so-called pharma ceutical glaze).

The coloring materials are preferably certified food colors; any of these may 'be employed. Wherethe un treated medicament is white, good contrast is obtained when the other portions are green and orange respectively. In this connection, use may be made, if desired, of F. D. &'C. Green No. 3 and D. & C. Orange No. 4, both 3,044,938 Patented July 17, 1962 L of which are certified food colors (specifications for both of these dyes are found in the bulletin issued September 1940S.R.A., F.D.C. 3, published by the Federal Security Agency on coal-tar color regulations). However, other non-toxic and pharmaceutically approved coloring materials may just as well be employed.

The invention is applicable to a wide variety of pharmaceuticals, as will be evident from the representative embodiments set forth in the following illustrative examples. In these examples the parts are by weight.

Example 1 This example illustrates the application of the invention to produce a sedative and antispasmodic tablet of sustained action.

Into a mixture of conventional pharmaceutical tablet ingredients consisting for example of 48 parts of corn starch, 145 parts of milk sugar and parts of powdered sugar, there are incorporated, as active ingredients, about 50 parts of phenobarbital and about 0.25 part of belladonna (e.g. in the form of Bellafoline). The mass is intimately and homogeneously admixed. To the resultant mixture, there is then added 0.8 part of gelatine dissolved in a small quantity (e.g. about 5 parts) of water, and 1 part of stearic acid dissolved in a small quantity (e.g. about 9 parts) of ether. Distilled water is then added until the mass has achieved the proper consistency for granulating. The mass is then granulated through a 5-6 cm. screen (5 to 6 meshes per centimeter), the thus-sized material being then dried, advantageously at to C. If desired, the dried materialwhich may be designated as the white granulation-may be further sized by being passed eg through a 45 cm. screen.

A second batch of material-which may be designated the green granulation-4s then made up from about 50 parts of phenobarbital, about 0.25 part of belladonna, about 157 parts of powdered sugar, and 2 parts of stearic acid, using as wetting agent a 50% by weight solution of about 50 parts of vinyl acetate (preferably as Bakelite Vinyl Resin AYAC) in methanol, which solution also contains 1 part of F. D. & C. Green No. 3. After the material is thoroughly mixed, it is broken up into lump form and dried at 'to C. Following elimination of all the methanol, the material is allowed to stand at room temperature (about 20 to 30 C.) until the granulation becomes hard. It is then broken up and sized through a 5-6 cm. screen, discarding any fine powder.

A third batch of materialwhich may be designated the orange granulation-is then made up from about 50 parts of phenobarbital, about 0.25 part of belladonna, about 167 parts of powdered sugar, and 2 parts of stearic acid, using as wetting agent a 60% by Weight solution of about 40 parts of refined shellac (pharmaceutical glaze) in methanol, which solution also contains 1 part of D. & C. Orange No. 4. The material is worked up essentially after the manner of the green granulation.

Equal weights of each batchwhite granulation, green granulation and orange granulation-are then thoroughly mixed together in a blender, after which the material is tahletted in conventional manner.

Each thus-prepared tablet will correspond essentially to the tablet illustrated (on enlarged scale) on the accompanying sheet of drawing, the respective parts being crosshatched to designate color, the white portions being free of cross-hatching.

Such a tablet will provide a sustained action-as compared to a tablet made exclusively of the white granulation. Moreover, the physician may prefer that the patient take the latter type of table during the day, and the sus-' tained type of tablet only before retiring; the variegated coloring of the sustained action tablet will thus enable the patient to distinguish between the two types.

Example 2 If it is desired to prepare a sustained action tablet with antispasmodic action but no sedative action, the procedure according to Example 1 is followed except that the phenobarbital is omitted throughout.

Example 3 A sustained action tablet may also be prepared essentially according to the procedure of Example 1, but omitting the orange granulation entirely. In this case, each tablet is conveniently constituted of equal parts by weight of the green granulation and of the white granulation.

Alternatively, the green granulation may be omitted and the tablets composed of equal parts by weight of the white and the orange granulations.

Example 4 In some cases, the normal granulation may also contain a color. This is exemplified for instance in the case of 5-ethyl-3-methyl-S-phenylhydantoin tablets, used for instance as an antiepileptic for grand mal seizures and psychomotor equivalents.

The first batch is prepared essentially after the manner described for the first batch in Example 1. It will here be a pink granulation, due to the incorporation of a small quantity of Erythrosine Dye Solution A%.

A second batch is prepared as a green granulation using vinyl acetate and green colorant after the manner described for the second batch in Example 1.

Finally, an orange granulation is prepared after the manner described for the orange granulation of Example 1, using refined shellac and orange colorant.

In each batch, the active ingredieut-preferably in the form of Mesantoin (Sandoz)-constitutes 50% by weight of the material.

Example 5 A sustained action tablet which is useful as an oxytocic and for migraine can be prepared essentially after the manner described in Example 1, using as active ingredient ergotamine tartrate, preferably as Cynergen (Sandoz), in an amount constituting about 2% by weight of each batch.

Example 6 Sustained action is frequently desirable in connection with antihistaminics. A sustained action tablet comprising white, green and orange granulations can be prepared after the manner of the foregoing examples using any desired antihistamine as the active ingredient. Thus, use may for example be made of 1-methyl-4-amino-N-phenyl- N-(2-phenyl)-piperidine tartrate, about 25 mg. per 220 mg. tablet, advantageously in the form of Sandostene (Sandoz).

It is evident from the foregoing that the principle of the invention is applicable to practically all types of tablet medication. In each case where the retardantbinder is used according to the invention, it is noteworthy that it is incorporated in dissolved form, so that such retardant-binder becomes just as much part of the respective mass or granulation as the medicaments or diluents themselves which are contained in such granulation. In other words, the mass of material in each such granulation is permeated by the wetting solution in which the retardant-binder has been previously dissolved, the material being manipulated so that a uniform mass results. On evaporating off the solvents, the retardant-binder becomes an integral part of the granulation and eventually of the tablets. No enteric coating action is hereby involved, as is evidenced inter alia by the fact that at least one granulation involves no retardant-binder at all. Even in the granulations which contain such retardant, the homogeneous character thereof distinguishes them from the enteric type of material.

Having thus disclosed the invention, what is claimed is:

A sustained action pharmaceutical tablet containing an active pharmaceutical ingredient and being conepaaess 5 stituted by a tabletted intimate and substantially uniform admixture of groups of granules, each granule of each group of granules comprising said active ingredient, the

active ingredient in each granule of at least one" group of with and free from disintegration retardant additarnent, 10

whereby each granule of the last mentioned group of granules may, upon coming into contact with body fluid, exert its function in normal manner and at normal rate, and the surface of said tablet comprising portions of dif- References Cited in the file of this patent UNITED STATES PATENTS 2,566,200 Hickey Aug. 28, 1951 2,687,367 Burrin Aug. 24, 1954 2,702,264 Klaui Feb. 15, 1955 2,738,303 Blythe Mar. 13, 1956 2,793,979 Svedres May 28, 1957 FOREIGN PATENTS 109,438 Australia Dec. 22, 1939 OTHER REFERENCES Tablet Coating, Clarkson, Drug and Cosmetic Indusferential disintegrability when in contact with said fluid. 15 try, 1951 (pages 55, 59 and 60 relied upon).

UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No 3 .044 ,938 July 17 1962 Stanley Halley It 15 hereby certified that error appears in the above numbered patent :z-equiiixx'g correction and that the said Letters Patent should read as corrected below.

Column 4, line 40, for "Cynergen" read "Gynergen Signed and sealed this 5th day of February, 1963.

(SEAL) Attest:

ERNEST W. SWIDER DAVID L. LADD Attesting Officer Commissioner of Patents

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2566200 *Jun 7, 1947Aug 28, 1951Commercial Solvents CorpOral therapeutic tablets
US2687367 *May 5, 1952Aug 24, 1954Lilly Co EliMedicinal tablet containing identification fragments
US2702264 *Mar 8, 1951Feb 15, 1955Hoffmann La RocheEnteric coated tablet
US2738303 *Jul 18, 1952Mar 13, 1956Smith Kline French LabSympathomimetic preparation
US2793979 *Mar 30, 1953May 28, 1957Smith Kline French LabMethod of making a sustained release pharmaceutical tablet and product of the method
AU109438B * Title not available
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3125490 *Aug 9, 1961Mar 17, 1964 Tablet with contrasting indicia and method
US3391477 *Oct 22, 1965Jul 9, 1968Abbott LabEducational model of pharmaceutical device
US3966899 *Mar 12, 1975Jun 29, 1976Yoshinobu NakaiMethod of treatment of medicines
US4012498 *Feb 19, 1976Mar 15, 1977Sandoz, Inc.Sustained release tablet formulations
US4503031 *Mar 12, 1984Mar 5, 1985Glassman Jacob ASuper-fast-starting-sustained release tablet
US4609542 *Jul 1, 1985Sep 2, 1986Elan Corporation, P.L.C.New pharmaceutical forms for administration of medicaments by oral route, with programmed release
US4673527 *May 20, 1985Jun 16, 1987Autotrol CorporationTablet granulation
US4704284 *Aug 12, 1982Nov 3, 1987Pfizer Inc.Long-acting matrix tablet formulations
US4720387 *Jun 5, 1984Jan 19, 1988Shionogi & Co., Ltd.Sustained-release preparation of pinacidil
US4726951 *Jul 1, 1985Feb 23, 1988Elan Corporation P.L.C.New pharmaceutical forms for administration of medicaments by oral route, with programmed release
US4794001 *Sep 24, 1987Dec 27, 1988American Home Products CorporationFormulations providing three distinct releases
US4888178 *Apr 12, 1989Dec 19, 1989Alfa Wassermann S.P.A.Galenic formulations with programmed release containing naproxen
US4904476 *Sep 30, 1988Feb 27, 1990American Home Products CorporationFormulations providing three distinct releases
U.S. Classification424/470
International ClassificationA61K9/20, A61K9/22
Cooperative ClassificationA61K9/2077
European ClassificationA61K9/20K2